Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + carboplatin + nitroglycerin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Transdermal
01
Overview
A combination therapy consisting of bevacizumab (a monoclonal antibody targeting VEGF), carboplatin (a platinum-based chemotherapy), paclitaxel (a taxane chemotherapy), and nitroglycerin (a vasodilator). This combination was studied in a randomized phase II trial for patients with stage IV non-squamous non-small cell lung cancer (NSCLC). The addition of nitroglycerin patches to the standard carboplatin-paclitaxel-bevacizumab regimen was hypothesized to improve outcomes by increasing tumor blood flow and oxygenation through inhibition of hypoxia-inducible-factor (HIF)-1.
02
Targets
sGC (Soluble Guanylyl Cyclase)HIF1A (Hypoxia-inducible factor 1-alpha)VEGFA (Vascular endothelial growth factor A)DNAMicrotubule
Beyond the preview
Go deeper on bevacizumab + carboplatin + nitroglycerin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + carboplatin + nitroglycerin + paclitaxel.